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timing of surgery and the RT schedule could influence tumor 
dissemination and subsequently patient overall survival. We 
demonstrated the impact of NeoRT on metastatic spreading 
in a Scid mice model. After an irradiation of 2x5gy, we show 
more metastasis in the lung when the mice are operated at 
day 4 compared to day 11 (1). Here, our aim is to evaluate 
with functional MRI (fMRI) the impact of the radiation 
treatment on the tumor microenvironment and subsequently 
to identify non-invasive markers helping to determine the 
best timing to perform surgery for avoiding tumor spreading. 
 
Material and Methods: We used two models of NeoRT in mice 
we have previously developed: MDA-MB 231 and 4T1 cells 
implanted in the flank of mice (1). When tumors reached the 
planned volume, they are irradiated with 2x5 Gy and then 
surgically removed at different time points after RT. 
Diffusion Weighted (DW) -MRI was performed every 2 days 
between RT and surgery. For each tumors we acquired 8 
slices of 1 mm thickness and 0.5 mm gap with an “in plane 
voxel resolution” of 0.5 mm. For DW-MRI, we performed 
FSEMS (Fast Spin Echo MultiSlice) sequences, with 9 different 
B-value (from 40 to 1000) and B0, in the 3 main directions. 
We also performed IVIM (IntraVoxel Incoherent Motion) 
analysis, in the aim to obtain information on intravascular 
diffusion, related to perfusion (F: perfusion factor) and 
subsequently tumor vessels perfusion.  
 
Results: With the MBA-MB 231 we observed a significant 
increase of F at day 6 after irradiation than a decrease and 
stabilization until surgery. No other modifications of the MRI 
signal, ADC, D or D* were observed. We observed similar 
results with 4T1 cells, F increased at day 3 than returned to 
initial signal (fig 1). The difference in the peak of F can be 
related to the difference in tumor growth between MBA-MB 
231 in four weeks and 4T1 in one week. 
 
 
Figure 1: Graphs representing F factor in tumor bearing mice 
before and after radiotherapy in MDA-MB 231(n=6) (Scid 
model) and in 4T1 (n=4) (BalbC model); (*=p<0, 05)  
 
Conclusion: For the first time, we demonstrate the 
feasibility of repetitive fMRI imaging in mice models after 
NeoRT. With these models, we show a significant difference 
between the pre-irradiated acquisition and day 6 or day 3 for 
perfusion F. This change occurs between the two previous 
time points of surgery demonstrating a difference in the 
metastatic spreading (1). These results are very promising for 
identifying noninvasive markers for guiding the best timing 
for surgery.  
Reference: (1) The timing of surgery after neoadjuvant 
radiotherapy influences tumor dissemination in a preclinical 
model Natacha Leroi et al. (2015) Oncotarget vol. 5 
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Purpose or Objective: To assess whether texture analysis of 
images obtained with Dual Energy CT (DECT) is related to 
KRAS and Ki-67 lung cancer biomarkers.  
 
Material and Methods: A retrospective review (May 2013 - 
January 2015) of 125 lung cancer patients with lung GSI 
(Gemstone Spectral Imaging) and perfusion CT imaging on a 
DECT was fulfilled. For 25 of them, the fraction of Ki-67 
positive-tumour cells was analysed and for 19 patients KRAS-
positive (mutation detected) or KRAS-negative (mutation not 
detected) character was evaluated (11 positive, 8 negative). 
DECT examination was performed on a Discovery CT 750 HD 
scanner (GE Healthcare, USA).  
For the perfusion exam, blood volume, blood flow and 
permeability-surface studies were analyzed. At GSI exam, 
images related to absorption in Hounsfield units (HU), iodine 
concentration and monochromatic virtual images 
reconstructed at 40, 60, 80, 100, 120 and 140 keV were 
assessed. Tumour fractal dimension was measured with the 
use of Mapfractalcount plug-in for ImageJ (National Institute 
of Health, USA) software.  
After extraction of DNA from paraffin embedded tissue using 
QIAamp DNA Investigator Kit (Qiagen), analysis of the KRAS 
gene exons 2 (codons 12/13) and 3 (codon 61) were 
performed in order to identify possible associated mutations 
with real-time PCR kit cOBAS® KRAS Mutation Test (Roche 
Diagnostics, SL).  
T-Student test or U Mann-Whitney test were used to compare 
differences between KRAS-positive from KRAS-negative 
cohorts. Pearson correlation coefficient was used to study 
linear relationship between fractal dimension and the 
fraction of Ki-67 positive-tumour cells.  
 
Results: Best result (p=0.02) for distinguishing KRAS-positive 
cohort was obtained for lesion fractal dimension at 140 keV 
virtual image. This parameter showed an AUC=0.80. It was 
predictive of KRAS-positive with 90.9% sensitivity and 75.0% 
specificity for a fractal dimension threshold of 2.352.  
There was a correlation of lesion fractal dimension in blood 
volume image and the fraction of Ki-67 positive-tumour cells 
(p= 0.04).  
 
 
 
Conclusion: Ki-67 positive-tumour cells and KRAS-positive 
biomarkers lead to tumour heterogeneity that modify 
radiographic image. Fractal dimension parameter quantifies 
such imaging heterogeneity and could allow to differentiate 
them.  
A higher fractal dimension (higher heterogeneity) of lesion at 
virtual monochromatic images is measured for KRAS-positive 
mutation, while a higher fraction of Ki-67 positive-tumour 
cells is associated with a more homogeneous blood volume at 
perfusion.  
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Purpose or Objective: The standard treatment regimen of 
patients with primary glioblastoma multiforme (PGBM) 
consists of neurosurgery, radio- and chemotherapy. Despite 
this multimodal treatment the overall survival of patients 
with PGBM is still approximately 15 months.  
The stress-inducible heat shock protein 70 (Hsp70) 
contributes to tumor cell survival and is associated with poor 
prognosis, metastasis and therapy resistance. Therefore, the 
aim of this study is to analyze Hsp70 in PGBM tumor samples 
as a future prognostic biomarker and possible therapy target. 
 
Material and Methods: Formalin fixed paraffin embedded 
(FFPE) sections of 44 human PGBM patients (isocitrate 
dehydrogenase wildtype) were analyzed by 
immunohistochemistry for Hsp70 (cmHsp70.1, IgG1, 
multimmune GmbH, Munich, Germany). Taking the intensity 
of Hsp70 staining into account, quantitative expression 
analysis of tumor cells with stained cytoplasm was 
performed. Two categories of Hsp70 staining were defined: 
Up to 40% and more than 40% positive tumor cells within the 
tumor regions. The Hsp70 immunoreactivity was correlated 
with the survival of the patients using the Cox regression 
analysis. 
 
Results: Preliminary data show that the median survival of 
PGBM patients can be predicted by the Hsp70 
immunoreactivity of the tumor cells. Regression analysis 
showed that patients with Hsp70 expression of more than 40% 
have a higher risk of disease progression with a hazard ratio 
of 2.59 (p= 0.045). 
 
 
 
Hsp70 expression in FFPE IHC section (Hsp70 positive tumor 
cells are brown) 
 
Conclusion: These data provide the first evidence that Hsp70 
expression in FFPE sections of PGBM patients is associated 
with disease progression. Moreover, measuring Hsp70 in FFPE 
sections of PGBM patients before radiotherapy treatment may 
be used as biomarker for the success of the therapy. The 
independency of Hsp70 expression and O6-methylguanin-DNA 
methyltransferase (MGMT) is currently under investigation. 
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Purpose or Objective: In recent years, it has been suggested 
that wound drainage fluids (WDF) of patients operated for 
head and neck squamous cell carcinoma (HNSCC) may be 
characterized by molecular biomarkers with potential 
prognostic and predictive value. The detection of adverse 
features in the early perioperative setting could possibly lead 
to a refinement of current adjuvant treatments in high-risk 
patients. The purpose of our study is to report on the 
feasibility and preliminary results of a pilot prospective study 
on WDF analysis in HNSCC. 
 
Material and Methods: 14 consecutive surgically resected 
HNSCCs were studied. WDF were collected 1 day and 3 days 
after surgery from the cancer operative bed (COB). In 5 
patients, WDF was collected also from free flap donor site 
(FFDS). WDF were centrifuged for 15 min at 3500 rpm, then 
divided in aliquots and stored at -80°C until analysis. The aim 
of the present study was to evaluate the expression of factors 
involved in tumor growth and progression 1 day and 3 days 
after surgery. EGF, VEGF, SDF-1 and osteopontin levels were 
measured in WDF using commercially available enzyme-linked 
immunosorbent assay (ELISA) kits. Each sample was analyzed 
in duplicates and then averaged for a mean value. Quality 
control pools of low, normal, or high concentrations for all 
parameters were included in each assay. The obtained results 
were expressed as pg/ml (EGF, VEGF, SDF-1 ) or ng/ml 
(osteopontin).  
 
Results: A mean of 67 ml of WDF from COB and 51 ml from 
FFDS at day 1, and 42 ml from COB and 20 ml from FFDS at 
day 3 were collected for each patient. EGF expression was 
significantly reduced from day 1 to day 3 after surgery both 
in COB (140.7±10.55 vs. 45.12±13.35 pg/ml, p<0.001) and in 
FFDS (157.1±4.08 vs. 95.59±32.89 pg/ml, p<0.05). VEGF 
expression increased from 1 to 3 day both in COB 
(1277.74±64.54 vs. 1616.81±151.4 pg/ml, p<0.05) and in FFDS 
(1227.51±19.39 vs. 1400.25±77.66 pg/ml, p<0.05). The 
expression of markers of invasiveness and metastasis 
increased from day 1 to day 3: osteopontin expression 
significantly increased from day 1 to day 3 both in COB 
(9.97±0.68 vs. 16.87±0.56 ng/ml, p<0.001) and in FFDS 
(9.51±1.23 vs. 15.83±1.08 ng/ml, p<0.01). SDF-1 expression 
increased from day 1 to day 3 in COB (646.8±65.39 vs. 
1084.22±148.8 pg/ml, p<0.05). No differences in SDF-1 
expression were detected in FFDS. 
 
Conclusion: Preliminary data from pilot study evidenced that 
microenvironment induced by surgery favors residual tumor 
cell proliferation and progression. Growth factor expression is 
higher early after surgery (24 hours); on the contrary, 
expression of markers of invasiveness and metastasis 
increases from day 1 to day 3 after surgery. The few samples 
of WDF from FFDS do not allow to evidence differences of 
biomarkers expression between COB and FFDS. 
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Purpose or Objective: Hematologic toxicity and in particular 
decrease in the peripheral blood leukocyte and lymphocyte 
count is an important side effect of pelvic radiation therapy. 
The aim of this study was to investigate the kinetic of the 
redistribution of circulating leukocytes after pelvic 
irradiation in a animal model with in vivo non-invasive 
imaging modality. 
